Symbicort efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Symbicort Efficacy in Asthma and COPD
Improved Lung Function and Asthma Control
Multiple studies show that Symbicort (budesonide/formoterol) is effective in improving lung function in both children and adults with asthma. In children not fully controlled on inhaled corticosteroids (ICS) alone, Symbicort led to significantly greater improvements in morning and evening peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) compared to budesonide alone MLEverard2001Pohunek2006. Similar benefits were observed in adults, where Symbicort provided greater increases in morning PEF, evening PEF, and clinic FEV1 compared to high-dose fluticasone propionate, along with reduced use of reliever medication and a lower risk of exacerbations . Studies in both mild/moderate and moderate/severe asthma in children and adults confirm rapid and significant improvements in lung function and symptom control with Symbicort Hongmei2011Yaling2008Wei-Wu2005.
Efficacy in COPD
In patients with chronic obstructive pulmonary disease (COPD), long-term use of Symbicort improved respiratory function (FVC, FEV1) and clinical symptoms, as measured by COPD-related questionnaires. The study also reported a reduction in COPD exacerbations, confirming Symbicort’s efficacy in routine clinical use for COPD management .
Symbicort SMART Regimen
The Symbicort Maintenance and Reliever Therapy (SMART) approach, which uses Symbicort as both a maintenance and reliever inhaler, was found to be at least as effective as conventional best practice with multiple inhalers. The SMART regimen resulted in similar or fewer severe asthma exacerbations, improved asthma control questionnaire scores, and allowed for a lower total corticosteroid dose and reduced drug costs . This simplified regimen was also well tolerated.
Symbicort Safety Profile
Adverse Events in Asthma and COPD
Across studies, Symbicort was generally well tolerated. Most adverse events were mild to moderate, with similar profiles to comparator treatments such as budesonide alone or fluticasone propionate MLEverard2001Bateman2003Pohunek2006. In children, no serious asthma-related adverse events were reported . In COPD patients, the most common adverse drug reactions were dysphonia, oropharyngeal discomfort, palpitations, bronchitis, oral candidiasis, pneumonia, and cough. Serious adverse events were rare and mostly unrelated to the drug, with a small number of cases of pneumonia and cardiovascular events possibly linked to treatment .
Safety in Children
Studies in children with asthma found Symbicort to be safe, with only minor side effects such as hoarseness and pharyngeal discomfort reported. No emergency treatments or need for additional short-acting beta2 agonists were observed during treatment periods MLEverard2001Hongmei2011Yaling2008+1 MORE.
Conclusion
Symbicort is an effective and well-tolerated treatment for asthma and COPD, providing significant improvements in lung function, symptom control, and reduction in exacerbations compared to ICS alone or other standard therapies. Its safety profile is favorable in both children and adults, with most adverse events being mild and manageable. The SMART regimen offers a simplified and cost-effective approach to asthma management with similar or better outcomes than conventional therapy.
Sources and full results
Most relevant research papers on this topic